# Chronic Obstructive Pulmonary Disease (COPD) Market

> Chronic obstructive pulmonary disease (COPD) Market Research Report Information By CPOD Type (Emphysema, Chronic Bronchitis), By Treatment Type (Drugs, Anti-Inflammatory Drugs, Surgery, Oxygen Therapy), By End Users (Hospitals & Clinics, Homecare Settings, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2035

- **Forecast Period:** 2025-2035
- **CAGR:** 8.50%
- **2025:** USD 32.10 Billion
- **2035:** USD 72.55 Billion
- **Key Players:** GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceutical, Viatris (Mylan), Chiesi Farmaceutici, Cipla

**Report ID:** MRFR/Pharma/1081-HCR · **Pages:** 90 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612

---

## Market Summary

The Global Chronic Obstructive Pulmonary Disease (COPD) Market size was valued at USD 22.07 Billion in 2024, and the market is projected to grow from USD 23.13 Billion in 2025 to USD 37.05 Billion by 2035, registering a CAGR of 4.82% during the forecast period 2025–2035.North America led the market with over 39.87% share, generating around USD 8.8 billion in revenue. 
 
The Chronic Obstructive Pulmonary Disease (COPD) Market is driven by rising prevalence of respiratory disorders, increasing exposure to smoking and air pollution, and growing adoption of advanced therapies, supporting demand for effective disease management and improved patient outcomes globally.
 
According to the World Health Organization (WHO), COPD is the third leading cause of death globally, causing over 3.2 million deaths annually, while the Institute for Health Metrics and Evaluation (IHME) highlights increasing disease burden, significantly driving demand for advanced COPD treatments and healthcare interventions.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Triple-combination inhaler adoption | ~1.8% | Global | Short-term (≤2 yr) | [6] |
| Biologics for eosinophilic COPD phenotypes | ~1.5% | North America, Europe | Medium-term (2–4 yr) | [7] |
| Medicare/payer shift to home-based care | ~1.3% | North America | Short-term (≤2 yr) | [5] |
| Connected-inhaler & remote monitoring adoption | ~1.2% | North America, Europe | Medium-term (2–4 yr) | [8] |
| EU F-gas propellant reformulation mandates | ~0.9% | Europe | Medium-term (2–4 yr) | [2] |
| Emerging-market spirometry infrastructure expansion | ~0.8% | Asia-Pacific | Long-term (≥4 yr) | [9] |
| AI-enabled exacerbation prediction platforms | ~0.6% | Global | Long-term (≥4 yr) | [10] |

### Triple-Combination Inhaler Adoption

Single-inhaler triple therapy (SITT) combining LABA, LAMA, and ICS has reshaped prescribing patterns across the Chronic Obstructive Pulmonary Disease Market since the FDA approval of fluticasone furoate/umeclidinium/vilanterol in 2017. Global SITT revenues exceeded USD 8.9 Billion in 2024, and formulary coverage now spans more than 85% of US commercial health plans.

### Biologics for Eosinophilic COPD Phenotypes

Sanofi/Regeneron’s dupilumab was the first biologic to show statistically significant exacerbation reductions in a Phase III eosinophilic COPD population, with a 30% risk reduction compared with placebo in the Phase III BOREAS trial [[7]](https://sanofi.com). The chronic obstructive pulmonary disease market is expected to capture USD 3-5 billion of new biologic spending by 2030 as more candidates (itepekimab, benralizumab, astegolimab) complete pivotal trials. The premium price – likely to be in the range of USD 15,000-25,000 per patient per year – will disproportionately boost revenues in North America and Western Europe.

### Medicare-Driven Shift to Home-Based Respiratory Care

CMS finalized reimbursement codes for Remote Patient Monitoring (RPM) of chronic respiratory conditions in 2019, enabling providers to bill CPT 99457/99458 for connected pulse oximetry and spirometry data review [[5]](https://cms.gov). This policy change directly expanded the addressable patient pool for home-based monitoring within the Chronic Obstructive Pulmonary Disease Market, with an estimated 1.6 million Medicare COPD beneficiaries eligible for RPM enrollment by 2026. Private payers including UnitedHealth and Aetna followed with similar coverage policies within twelve months.

### Connected-Inhaler and Remote Monitoring Adoption

Digital health businesses such as Propeller Health (bought by ResMed) and Adherium have developed Bluetooth-enabled inhaler sensors that provide dosing data to cloud platforms for physician intervention before exacerbations get worse [[8]](https://thelancet.com). The evidentiary basis presently required by payers for premium reimbursement tier placement in the Chronic Obstructive Pulmonary Disease Market was established in real-world evidence published in The [Lancet](https://www.marketresearchfuture.com/reports/lancet-market-2078) Respiratory Medicine showing a 58% improvement in adherence in connected-inhaler users.

## Restraints

## Restraints Impact Analysis

Restraint impact estimates follow the same directional methodology described in Section 4. Negative values indicate downward pressure on segment or total-market growth.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Generic erosion of first-generation LABA/LAMA therapies | –1.2% | Global | Short-term (≤2 yr) | [11] |
| Propellant transition costs and supply disruption | –0.8% | Europe | Medium-term (2–4 yr) | [2] |
| Under-diagnosis in low-income populations | –0.7% | Asia-Pacific, MEA | Long-term (≥4 yr) | [12] |
| Tobacco cessation program success reducing incidence | –0.5% | North America, Europe | Long-term (≥4 yr) | [13] |
| Reimbursement complexity for combination devices | –0.4% | North America | Medium-term (2–4 yr) | [14] |

### Generic Erosion of First-Generation Bronchodilators

Tiotropium (Spiriva) and a number of LABA compounds have lost patent protection and are now paving the way for authorized generics and device-specific copies, with average selling prices falling by 35–50% in areas with substitution regulations [[11]](https://fda.gov). This erosion puts downward pressure on prices across the Chronic Obstructive Pulmonary Disease Market, which partially offsets volume increases stemming from expanded diagnostic and treatment commencement.

### Under-Diagnosis in Low-Income Settings

The WHO estimates that fewer than 30% of COPD cases are diagnosed in Sub-Saharan Africa and South Asia, where access to spirometry remains limited to tertiary hospitals [[12]](https://who.int). This diagnostic gap constrains the effective addressable market, particularly for higher-margin combination therapies, and limits the realized growth of the Chronic Obstructive Pulmonary Disease Market in regions that otherwise show high prevalence rates linked to biomass fuel exposure.

## Opportunities

## Chronic Obstructive Pulmonary Disease (COPD) Market Opportunities

### Biologic Pipeline Expansion Beyond Eosinophilic Subtypes

While early biologic approvals target eosinophilic phenotypes, next-generation candidates addressing neutrophilic and mixed-inflammatory COPD could unlock an additional patient pool of over 100 million adults globally. Companies advancing anti-TSLP and anti-IL-33 pathways are positioning for pivotal readouts by 2028, potentially broadening the premium tier of the Chronic Obstructive Pulmonary Disease Market.

### Digital Therapeutics and Data Monetization

Connected-inhaler platforms generate longitudinal adherence and symptom datasets that pharmaceutical manufacturers, payers, and health systems increasingly value for outcomes-based contracting.

### Emerging-Market Infrastructure Build-Out

India’s Ayushman Bharat Digital Mission and China’s Healthy China 2030 strategy are investing > USD 4 billion on primary-care diagnostics including point-of-care spirometry at community health centers[[9]](https://mohfw.gov.in). These expenditures will bring millions of unidentified patients into the formal treatment pathways and will significantly boost the Chronic Obstructive Pulmonary Disease Market in Asia Pacific.

### Low-GWP Inhaler Reformulation Lifecycle Refresh

The regulatory-mandated phase-out of HFA-134a propellants in Europe creates a product-lifecycle reset for every pressurized metered-dose inhaler on the market. Manufacturers that achieve early approval for HFA-152a formulations can secure two to three years of limited competition and premium pricing, turning an environmental mandate into a revenue-acceleration event within the Chronic Obstructive Pulmonary Disease Market.

### Hospital-at-Home Models for Acute Exacerbation Management

Management of moderate COPD exacerbations in the home setting was shown to reduce 30-day readmission rates by 27% and per-episode costs by USD 3,400 in pilot programs at Kaiser Permanente and NHS England [[15]](https://kp.org). As these models scale, they create demand for portable nebulizers, connected monitoring kits, and telemedicine platforms across the Chronic Obstructive Pulmonary Disease Market.

## Future Outlook

## Chronic Obstructive Pulmonary Disease (COPD) Market Future Outlook

### AI-Driven Clinical Decision Support

Machine-learning models trained on connected-device data are moving from research prototypes to reimbursable clinical tools. By 2030, predictive exacerbation alerts could prevent an estimated 2.3 million emergency department visits in the US alone, fundamentally altering the care-delivery economics of the Chronic Obstructive Pulmonary Disease Market.

### Precision Medicine and Biomarker-Guided Therapy

Blood eosinophil counts have emerged as the first validated [biomarker](https://www.marketresearchfuture.com/reports/biomarker-market-1941) for COPD treatment selection, but next-generation companion diagnostics targeting fractional exhaled nitric oxide (FeNO) and airway microbiome signatures promise far more granular phenotyping [[19]](https://atsjournals.org). The Chronic Obstructive Pulmonary Disease Market will increasingly stratify into biomarker-defined micro-segments, each with distinct therapeutic agents and reimbursement tiers, mirroring the evolution seen in oncology over the past decade.

### Sustainability and Green Inhaler Transition

The Montreal Protocol's Kigali Amendment and the EU F-gas Regulation are creating a decade-long product-transition cycle. The switch from HFA-134a to HFA-152a propellants reduces per-inhaler carbon footprint by approximately 90%, but requires complete device-formulation redevelopment [[2]](https://ec.europa.eu). By 2032, low-GWP inhalers are expected to constitute over 65% of European pMDI prescriptions, reshaping supply-chain partnerships across the Chronic Obstructive Pulmonary Disease Market.

### Value-Based and Outcomes-Linked Contracting

Payers and manufacturers are piloting outcomes-based agreements tied to exacerbation frequency and hospitalization rates. These contracting models will redefine competitive positioning in the Chronic Obstructive Pulmonary Disease Market, rewarding manufacturers that invest in adherence platforms and companion digital tools.

## Segment Insights

## Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation

### By Product Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Drug Class | 69.50% share (2024) | Triple-combination inhaler adoption |
| Diagnostic Devices | USD 3.42 Billion (2024) | Screening guideline expansion |
| Monitoring Devices | 9.60% CAGR (2026–2035) | Remote patient monitoring reimbursement |
| Consumables & Accessories | 8.00% CAGR (2026–2035) | Recurring replacement cycles |

Drug Class therapies form the revenue backbone of the Chronic Obstructive Pulmonary Disease Market, anchored by blockbuster LABA/LAMA/ICS combinations such as Trelegy Ellipta (GSK) and Breztri Aerosphere (AstraZeneca). The shift from dual to triple therapy has expanded average prescription values by approximately 40% over three years, and biologic entrants will add a premium pricing tier on top of established inhaler revenue by 2028.

Monitoring Devices represent the fastest-growing product segment in the Chronic Obstructive Pulmonary Disease Market, driven by CPT code expansion for remote spirometry and pulse oximetry. Manufacturers including ResMed and Masimo are embedding cellular connectivity directly into devices, eliminating the need for smartphone pairing and lowering adoption barriers among elderly COPD patients.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals and Clinics | 83.30% share (2024) | Acute exacerbation management |
| Homecare Settings | 7.30% CAGR (2026–2035) | Payer shift to outpatient care |
| Other End Users | USD 1.10 Billion (2024) | Occupational health programs |

Hospitals and clinics continue to dominate spending in the Chronic Obstructive Pulmonary Disease Market because severe exacerbations requiring nebulized therapy, supplemental oxygen, and emergency diagnostics are resource-intensive episodes. Homecare settings are the clear growth story, as payer incentives to reduce 30-day readmission rates push monitoring, maintenance therapy, and telehealth encounters into community and residential environments.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 40.80% share (2024) | Biologics launch, RPM reimbursement |
| Europe | USD 9.15 Billion (2024) | Propellant transition, value-based care |
| Asia-Pacific | 7.90% CAGR (2026–2035) | Spirometry capacity, generic access |
| South America | USD 1.98 Billion (2024) | Public formulary expansion |
| Middle East & Africa | 5.80% CAGR (2026–2035) | Diagnostic infrastructure |
| Total | USD 32.10 Billion (2025) | — |

The Chronic Obstructive Pulmonary Disease Market exhibits a distinct geographic hierarchy shaped by reimbursement structures, diagnostic penetration rates, and disease burden demographics. North America remains the largest revenue contributor, while Asia-Pacific is closing the gap through infrastructure-led volume expansion.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 82.40% of regional share | Medicare Part D biologic coverage |
| Canada | 10.70% of regional share | Provincial formulary harmonization |
| Mexico | 6.90% of regional share | Seguro Popular expansion |

The US dominates North America's Chronic Obstructive Pulmonary Disease Market, with CMS reimbursement policy acting as the single largest demand lever. The Inflation Reduction Act's Part D redesign, effective 2025, caps out-of-pocket costs for inhaler therapies at USD 2,000 annually, expanding treatment affordability for an estimated 3.8 million Medicare beneficiaries [[16]](https://cms.gov). Canada's pan-Canadian Pharmaceutical Alliance continues negotiating lower list prices for combination inhalers, while Mexico is integrating COPD screening into its primary-care expansion under IMSS-Bienestar.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 8.50% CAGR (2026–2035) | AMNOG fast-track for respiratory biologics |
| UK | USD 1.62 Billion (2024) | NHS Long Term Plan respiratory targets |
| France | 16.20% of regional share | Social security inhaler reimbursement |
| Italy | 12.80% of regional share | Regional health authority procurement |
| Spain | 5.90% CAGR (2026–2035) | National COPD strategy implementation |
| Nordic Countries | USD 0.78 Billion (2024) | Digital health integration |
| Russia | 4.10% of regional share | State pharma procurement programs |
| Rest of Europe | 7.50% of regional share | EU HTA joint assessment framework |

Europe's Chronic Obstructive Pulmonary Disease Market is defined by the tension between cost-containment frameworks and the push for innovative therapies. The EU HTA Regulation, effective January 2025, introduces joint clinical assessments that will accelerate access decisions across member states while applying downward pricing pressure through cross-referencing [[17]](https://ec.europa.eu). The UK's NHS Long Term Plan has set a target of reducing COPD emergency admissions by 25% by 2028, driving investment in community-based care models.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 35.60% of regional share | National essential medicines list expansion |
| India | 9.20% CAGR (2026–2035) | Ayushman Bharat diagnostics program |
| Japan | USD 2.15 Billion (2024) | NHI tiotropium reimbursement reform |
| South Korea | 7.80% CAGR (2026–2035) | HIRA formulary inclusion |
| ASEAN | 14.30% of regional share | Generic inhaler manufacturing hubs |
| Rest of Asia-Pacific | 5.50% of regional share | WHO PEN program adoption |

China represents the largest volume opportunity in the Chronic Obstructive Pulmonary Disease Market across Asia-Pacific, though reimbursement per patient remains below Western averages. The 2024 update to China's National Reimbursement Drug List added three new COPD combination therapies, while India's production-linked incentive scheme for inhalation devices is attracting USD 800 million in domestic manufacturing investment through 2027 [[9]](https://mohfw.gov.in).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.30% of regional share | SUS formulary inhaler inclusion |
| Argentina | 6.40% CAGR (2026–2035) | Private health plan expansion |
| Rest of South America | USD 0.55 Billion (2024) | Pan-American respiratory health initiative |

Brazil anchors South America's Chronic Obstructive Pulmonary Disease Market through the Unified Health System (SUS), which added long-acting muscarinic antagonists to its essential medicines list in 2023. Access remains uneven outside major urban centers, and high out-of-pocket costs for combination therapies limit uptake in lower-income brackets.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.40% of regional share | Vision 2030 healthcare transformation |
| UAE | USD 0.32 Billion (2024) | Private hospital expansion |
| South Africa | 6.10% CAGR (2026–2035) | NHI pilot respiratory integration |
| Egypt | 14.70% of regional share | Biomass-exposure screening programs |
| Rest of MEA | 26.20% of regional share | NGO-funded diagnostic campaigns |

The Middle East & Africa segment of the Chronic Obstructive Pulmonary Disease Market remains the smallest by revenue but shows accelerating growth as Gulf states invest in specialized respiratory centers. Saudi Arabia's Vision 2030 healthcare transformation includes dedicated COPD management pathways within its expanded primary-care network, while South Africa's NHI pilot programs are integrating spirometry into community clinic workflows [[18]](https://moh.gov.sa).

## Competitive Benchmarking

## Competitive Benchmarking

The Chronic Obstructive Pulmonary Disease Market exhibits moderate concentration, with the top five companies commanding an estimated 55–62% of global revenue. The Herfindahl-Hirschman Index sits in the 1,200–1,500 range, indicative of a market where a handful of large pharmaceutical companies hold dominant positions in inhalers and drug therapies while device and digital-health specialists occupy fragmented niches.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| GlaxoSmithKline (GSK) | ~14–18% | Trelegy Ellipta, Anoro, Nucala | Triple-therapy market leader, biologic expansion |
| AstraZeneca | ~12–15% | Breztri Aerosphere, Saphnelo pipeline | Combination inhaler + biologics dual strategy |
| Boehringer Ingelheim | ~10–13% | Spiriva, Stiolto Respimat | LAMA franchise, connected-device partnerships |
| Novartis | ~6–9% | Ultibro Breezhaler, Enerzair | Inhaler-sensor integration, outcomes contracts |
| Teva Pharmaceutical | ~4–7% | ProAir, generic tiotropium | Generic bronchodilator portfolio |
| Viatris (Mylan) | ~3–5% | Breyna, Wixela Inhub | Authorized-generic inhalers |
| Chiesi Farmaceutici | ~3–5% | Trimbow, Foster | Low-GWP propellant pioneer |
| Cipla | ~2–4% | DPI portfolio, Aerobika device | Emerging-market access leader |
| Sanofi/Regeneron | ~2–4% | Dupixent (eosinophilic COPD) | First biologic entrant for COPD |
| ResMed | ~2–3% | Propeller Health platform, AirMini | Digital adherence and RPM platform |

## Recent News & Developments

## Recent News & Developments

- Sanofi/Regeneron (September 2024): Received FDA approval for dupilumab in eosinophilic COPD, marking the first biologic indicated for COPD management and opening a projected USD 3 billion revenue opportunity by 2030 [[7]](https://sanofi.com).

- European Commission (January 2025): Published updated F-gas Regulation implementation guidelines, establishing a 2050 deadline for HFA-134a phase-out in metered-dose inhalers across all member states [[2]](https://ec.europa.eu).

- Chiesi Farmaceutici (August 2024): Completed first commercial-scale production runs of its HFA-152a reformulated Trimbow inhaler at its Parma facility, positioning as the first-mover in low-GWP pMDI delivery in Europe [[23]](https://chiesi.com).
- CMS (December 2019): Finalized RPM billing codes CPT 99457/99458 for chronic respiratory conditions, extending Medicare coverage to connected inhaler and spirometry monitoring services [[5]](https://cms.gov).

## Report Scope

## Chronic Obstructive Pulmonary Disease (COPD) Market Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Drug Class therapies, Diagnostic Devices, Monitoring Devices, Consumables & Accessories for COPD management |
| Study Period | 2021–2035 |
| CAGR (2026–2035) | 8.50% |
| Base Year Market Size (2025) | USD 32.10 Billion |
| Forecast Endpoint (2035) | USD 72.55 Billion |
| Fastest Growing Segment | Monitoring Devices (9.60% CAGR) |
| Companies Profiled | 10 (GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Teva, Viatris, Chiesi, Cipla, Sanofi/Regeneron, ResMed) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How does the shift from HFA-134a to HFA-152a propellants affect inhaler pricing for COPD patients?**
A: Reformulated inhalers typically launch at a 10–15% price premium over existing versions because manufacturers must recoup device-redesign costs. Prices tend to normalize within three to four years as competitor entries and payer negotiations apply downward pressure [2].

**Q: What role do companion diagnostics play in biologic prescribing for COPD?**
A: Blood eosinophil count testing is now required before biologic initiation, adding an estimated USD 50–120 per patient in diagnostic costs. This requirement creates a new revenue stream for laboratory and point-of-care testing companies [19].

**Q: How are value-based inhaler contracts structured between manufacturers and payers?**
A: Rebate levels are linked to measurable outcomes such as 90-day exacerbation rates or emergency-department utilization, tracked through claims data. Manufacturers that invest in adherence platforms gain negotiating leverage [20].

**Q: What distinguishes the Chronic Obstructive Pulmonary Disease Market opportunity in India versus China?**
A: India's growth is volume-driven through public-sector spirometry rollout at community health centers. China's growth combines volume expansion with faster adoption of premium combination inhalers through its national drug reimbursement list [9].

**Q: How does connected-inhaler data ownership affect competitive dynamics in the Chronic Obstructive Pulmonary Disease Market?**
A: Companies controlling adherence data platforms hold negotiating power with payers seeking real-world evidence for formulary decisions. Device-agnostic platforms like Propeller Health attract broader manufacturer partnerships than proprietary systems [8].

**Q: What is the anticipated impact of biosimilar bronchodilators on the Chronic Obstructive Pulmonary Disease Market?**
A: Biosimilar and device-generic entries are expected to reduce average selling prices for first-generation LABA/LAMA therapies by 35–50% by 2029. This compresses revenue from older molecules while accelerating patient access [11].

**Q: How will the EU HTA Regulation change market-access timelines for new COPD therapies?**
A: Centrally authorized COPD respiratory therapies will integrate into the mandatory Joint Clinical Assessment framework starting in January 2030, establishing a single, unified European clinical evidence baseline designed to eliminate duplicative member-state assessments.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612*